This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Astellas Pharma Gmbh. Active years: 2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019
Title: Junko Yarimizu: Pharmaceutical Invention and Patent
Introduction
Junko Yarimizu is an inventor associated with Tokyo, Japan, and Astellas Pharma GmbH. Her patent work concerns a pharmaceutical compound designed to modulate dopamine D1 receptors.
Latest Patents
Yarimizu is named on 1 patent, titled “Imidazodiazepine compound.” The patent describes compounds that act as dopamine D1 receptor positive allosteric modulators, or D1 PAMs. These compounds may be used as active ingredients in pharmaceutical compositions intended to prevent or treat cognitive impairment, negative symptoms of schizophrenia, cognitive impairment associated with schizophrenia, Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, depression, ADHD, and drug dependency.
Career Highlights
Yarimizu’s listed invention reflects research into potential therapeutic applications of dopamine D1 receptor modulation. The patent identifies Astellas Pharma GmbH as her associated company.
Collaborations
Tomoyoshi Imaizumi and Naoyuki Masuda are identified as Yarimizu’s coworkers.
Conclusion
Junko Yarimizu’s patent on an imidazodiazepine compound highlights her contribution to pharmaceutical research exploring potential treatments for neurological and psychiatric conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile